|
2012, Volume 28, Number 3, Page(s) 220-230
|
|
DOI: 10.5146/tjpath.2012.01128 |
Expression of p16, p53, CD24, EpCAM and Calretinin in Serous Borderline Tumors of the Ovary |
Işıl Yildiz AKTAŞ, Meral BUĞDAYCI, Alp USUBÜTÜN |
Department of Pathology, Hacettepe University, Faculty of Medicine, ANKARA, TURKEY |
Keywords:
Ovary, Tumor, p16 protein, p53 antigen, CD24 antigen, EpCAM protein, Calretinin |
Objective: According to the widely accepted pathway, a serous
borderline tumor becomes invasive either by progressing into a
noninvasive micropapillary tumor or directly through microinvasion.
Our objective was to investigate the role of serous borderline tumors
and their accompanying extraovarian lesions in pathogenesis of
serous ovarian cancer using immunohistochemistry as a tool.
Material and Method: An immunohistochemical panel of p16, p53,
CD24, EpCAM and calretinin was applied to cutting edge matrix
assembly-like tissue arrays of 46 cases consisting of typical, focal
micropapillary, micropapillary, microinvasive, cystadenoma, and
low-grade carcinoma cases. These tissue arrays are better choices than
conventional tissue arrays to examine thin walled and heterogenous
neoplasia like serous borderline tumors as they facilitate the analysis
with linear sections rather than a core.
Results: For two tumor supressor gene markers; no diffuse and strong
expression of p53, and strong and patchy/heterogenous expression of
p16 were detected in all cases. Focal and strong calretinin expression
was detected in micropapillary tumors while expression of EpCAM
was lost in the same areas. Strong cytoplasmic CD24 expression was
detected in cases with peritoneal implants, favoring the theory that
change of expression localization of cell adhesion molecules is in accordance
with phenotypical changes and tumor progresssion. Furthermore,
circumfrential membranous and cytoplasmic expression of
CD24 and EpCAM was detected in neoplastic cells in lymph nodes
and microinvasion areas.
Conclusion: Our results show that different levels of serous
ovarian tumor progression are accompanied by changes in the
immunohistochemical expression pattern of EpCAM, CD24, and
calretinin.
|
|
|
|